| Literature DB >> 24626548 |
Suely Rozenfeld, Fabiola Giordani, Sonia Coelho.
Abstract
OBJECTIVE: To estimate the frequency of and to characterize the adverse drug events at a terciary care hospital.Entities:
Mesh:
Year: 2013 PMID: 24626548 PMCID: PMC4206103 DOI: 10.1590/s0034-8910.2013047004735
Source DB: PubMed Journal: Rev Saude Publica ISSN: 0034-8910 Impact factor: 2.106
Characteristics of the hospitalized patients according to occurrence of adverse drug events, identified using triggers in a federal hospital. Rio de Janeiro, RJ, Southeastern Brazil, 2007.
| Variable | No ADE | ADE | Total | P[ | ||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |||
| Mean age[ | 53.3(17.3) | – | 52.8(18.2) | – | 53.2(17.4) | – | 0.908 | |
| Sex | 0.988 | |||||||
| Female | 65 | 84.4 | 12 | 15.6 | 77 | 60.2 | ||
| Male | 43 | 84.3 | 8 | 15.7 | 51 | 39.8 | ||
| Race/Skin color | 0.919 | |||||||
| White | 48 | 82.8 | 10 | 17.2 | 58 | 48.7 | ||
| Black | 19 | 86.4 | 3 | 13.6 | 22 | 18.5 | ||
| Mixed race | 33 | 84.6 | 6 | 15.4 | 39 | 32.8 | ||
| Schooling | 0.57 | |||||||
| Did not finish primary education | 54 | 80.6 | 13 | 19.4 | 67 | 73.6 | ||
| Did not finish secondary education | 18 | 90.0 | 2 | 10.0 | 20 | 22.0 | ||
| Further education | 3 | 75.0 | 1 | 25.0 | 4 | 4.4 | ||
| Occupation | 0.037 | |||||||
| Retired | 37 | 82.2 | 8 | 17.8 | 45 | 47.9 | ||
| Homemaker | 12 | 70.6 | 5 | 29.4 | 17 | 18.1 | ||
| Other | 31 | 96.9 | 1 | 3.1 | 32 | 34.0 | ||
| CCI | 0.312 | |||||||
| 0 | 67 | 87.0 | 10 | 13.0 | 77 | 60.2 | ||
| ≥ 1 | 41 | 80.4 | 10 | 19.6 | 51 | 39.8 | ||
| Mean length of hospitalization (days)[ | 10.7(15.3) | – | 35.2(28.0) | – | 14.6(19.9) | – | < 0.01 | |
CCI: Charlson Comorbidity Index; ADE: adverse drug event
Chi-square or Fisher’s exact tests for categorical variables and Student’s t test for continual variables.
The values shown are the means and, in brackets, the respective standard deviation.
FigureFlowchart representing the study population and the adverse drug events identified using triggers in a federal hospital. Rio de Janeiro, RJ, Southeastern Brazil, 2007.
E = temporary harm to the patient and need for intervention; F = temporary harm to the patient and need for intervention or prolongation of hospitalization; I = death; ADE: Adverse Drug Events
Frequency of triggers identified, of adverse drug events identified and Positive Predictive Value in a federal hospital. Rio de Janeiro, RJ, Southeastern Brazil, 2007.
| List of triggers | Trigger per 100 medical records | Adverse drug events per 100 medical records | Positive Predictive Value[ |
|---|---|---|---|
| Antihistamines (dexchlorpheniramine, loratadine, promethazine and epinephrine) | 7.0 | 0.0 | 0.0 |
| Coagulants (vitamin K1 and protamine) | 4.7 | 0.8 | 16.7 |
| Benzodiazepine antagonist (flumazenil) | 0.0 | 0.0 | – |
| Anti-emetic (bromopride, metoclopramide and ondansetron) | 58.6 | 7.0 | 12.0 |
| Opioid antagonist (naloxone) | 0.0 | 0.0 | – |
| Anti-diarrhea (loperamide) | 1.6 | 0.0 | 0.0 |
| Ion-exchange resin (calcium polystyrene sulfonate) | 0.8 | 0.0 | 0.0 |
| Blood sugar < 50 mg/dL | 2.3 | 0.8 | 33.3 |
| PTT > 100 seconds | 0.0 | 0.0 | – |
| INR > 6 | 0.0 | 0.0 | – |
| Leucocytes < 3.000 | 1.6 | 0.0 | 0.0 |
| Platelets < 50.000 | 0.8 | 0.0 | 0.0 |
| Use of digoxin and arrhythmia, bradycardia, nausea, vomiting, anorexia, or visual changes | 2.3 | 0.8 | 33.3 |
| Elevated serum creatinine | 8.6 | 1.6 | 18.2 |
| Excessive drowsiness, lethargy, fall, hypotension | 27.3 | 7.0 | 25.7 |
| Rash | 0.8 | 0.8 | 100.0 |
| Sudden interruption of medication | 63.3 | 7.8 | 12.4 |
| Transfer to a higher level of care | 5.5 | 0.0 | 0.0 |
| Total | 185.2 | 26.6 | 14.4 |
PPV = nº of medical records in which the trigger indicated ADE x 100/nº of medical records in which the trigger indicated ADE + nº of medical records in which the trigger did not indicate ADE. The denominator is the number of times the trigger occurred, indicating, or not, ADE. Example: anti-emetic: 7.0 x 100/58.6 = 12.0.
Description of adverse drug events, medication implicated and degree of harm suffered by the patient, in a federal hospital. Rio de Janeiro, RJ, Southeastern Brazil, 2007.
| Adverse drug events | Number of cases | %[ | Medications implicated | Degree of harm |
|---|---|---|---|---|
| Nausea and/or vomiting | 10 | 29.4 | Dipyrone | E |
| Ceftriaxone | E | |||
| Deslanoside | E | |||
| Tramadol | E | |||
| Cefazolin | E | |||
| Ciprofloxacin | E | |||
| Levofloxacin + tramadol | E | |||
| Indomethacin + levofloxacin | E | |||
| Metronidazole + tramadol + clindamycin + dipyrone + ranitidine | E | |||
| Drowsiness | 5 | 14.7 | Tramadol | E |
| Clonazepam | E | |||
| Metoclopramide | E | |||
| Diazepam | E | |||
| Promethazine | E | |||
| Hypoglycemia | 4 | 11.8 | Glibenclamide + metformin | E |
| Glibenclamide | E | |||
| Insulin | E | |||
| Lipothymy | 3 | 8.8 | Furosemide + dipyrone + metoclopramide | E |
| Propranolol + hydrochlorothiazide | F | |||
| Levothyroxine | E | |||
| Hypotension | 2 | 5.9 | Captopril + furosemide + amlodipine + atenolol | E |
| Captopril + spironolactone + isosorbide + furosemide | I | |||
| Renal failure | 2 | 5.9 | Simvastatin | I |
| Amphotericin B | E | |||
| Pruritus | 2 | 5.9 | Clindamycin | F |
| Vancomycin | E | |||
| Falls | 2 | 5.9 | Diazepam + dexchlorpheniramine | F |
| hydroxyzine | F | |||
| Hemorrhage | 2 | 5.9 | Enoxaparin | E |
| Arrhythmia | 1 | 2.9 | Digoxin + omeprazole + carvedilol | E |
| Diarrhea | 1 | 2.9 | Lactulose | E |
E = temporary harm to the patient and the need for intervention, F = temporary harm to the patient and the need for hospitalization or prolongation of hospitalization, I = death
The number of cases does not match the number of rows in the “ Medications implicated” column because there are repeated EAM-drug pairs (dipyrone-nausea = 2 instances hypoglycemia-glibenclamide + metformin = 2 cases, and hemorrhage-enoxaparin = 2 cases).
Classes of medications related to an adverse drug event according to the first and second levels of the Anatomical Therapeutic Chemical classification in a federal hospital. Rio de Janeiro, RJ, Southeastern Brazil, 2007.
| Code - Anatomical Therapeutic Chemical classification group | n | Proportion (%) | |
|---|---|---|---|
| A - Digestive tract and metabolism | 11 | 20.4 | |
| A02 - Agents related to acid disorders | 2 | 3.7 | |
| A03 - Agents for function gastrointestinal disorders | 2 | 3.7 | |
| A06 - Laxatives | 1 | 1.9 | |
| A10 - Medications used in diabetes | 6 | 11.1 | |
| B - Blood and blood forming organs | 2 | 3.7 | |
| B01 - Antithrombotic medication | 2 | 3.7 | |
| C - Cardiovascular system | 15 | 27.8 | |
| C01 - Cardiac therapy | 3 | 5.6 | |
| C03 - Diuretics | 5 | 9.3 | |
| C07 - Beta-blocking agents | 3 | 5.6 | |
| C08 - Calcium channel blockers | 1 | 1.9 | |
| C09 - Agents acting on the renin-angiotensin system | 2 | 3.7 | |
| C10 - Agents modifying the lipid profile | 1 | 1.9 | |
| H - Systemic hormonal preparations, excluding sex hormones and insulins | 1 | 1.9 | |
| H02 - Corticosteroids for systemic use | 1 | 1.9 | |
| J - General anti-infectives for systemic use | 10 | 18.5 | |
| J01 - Anti-bacterials for systemic use | 9 | 16.7 | |
| J02 - Anti-mycotics for systemic use | 1 | 1.9 | |
| M - Musculoskeletal System | 1 | 1.9 | |
| M01 - Anti-inflammatory and anti-rheumatic drugs | 1 | 1.9 | |
| N - Nervous system | 12 | 22.2 | |
| N02 - Analgesics | 8 | 14.8 | |
| N03 - Anti-epileptics | 1 | 1.9 | |
| N05 - Psycholeptics | 3 | 5.6 | |
| R - Respiratory system | 2 | 3.7 | |
| R06 - Anti-histamine for systemic use | 2 | 3.7 | |
| Total | 54 | 100.0 | |
n: number of times the medication class was associated with an ADE